Ty -jour t1-在荷贝（Epicenter）和河内外部治疗的Covid -19患者的临床特征和结果（非剧本）：中国的全国性分析 - 欧洲呼吸道 - 欧洲呼吸杂志JO -EUR RESSIR J -EUR RESSIR J DO -10.1183/ 10.1183/ do13993003.00562-2020 VL -55 IS -6 sp -2000562 au -liang，wen -hua au -guan -guan，wei -jie au -li -li，cai -chen au -li -li -li，yi -min au -liang -liang，heng -rui au -zhao -Zhao -Zhao -Zhao -Zhao -Zhao，yi au -liu，小黄色 - 唱歌，ling au -chen，ru -chong au -tang，chun -li au -wang -wang，tao au -wang -wang，wei au-他，qi -hua au--sheng au -wong，sook -san au -Zanin，Mark au -liu -jun au -xu -xu，xin au -huang -juan au -jun au -li -li，jian -fu au -ou -ou -ou，li -min au -au -cheng -cheng，bo au--Xiong，Shan au -xie，Zhan -hong au -ni，Zheng -yi au -hu，Yu au -yu -liu，lei au -shan，hong au -lei -lei -chun -liang au -peng -peng -peng -peng -pen -yi -xiang au -wei -wei -wei，li au -liu，Yong au -hu，ya -hua au -peng，peng au -wang，jian -ming au -liu -ji -yang au -chen，chen，zhong au -li -li -li，gang au -zheng -zheng，Zhi -jian au-qiu，shao -qin au -luo，jie au -ye，chang -jiang au -zhu，shao -yong au -cheng，lin -ling au -ye -ye，feng au -li，shi -yue au -zheng -zheng，jin -ping au -Zhang -Zhang，nuo -fu au-，Nan -shan au -He，Jian -Xing Y1-2020/06/01 Ur -http：//www.qdcxjkg.com/content/55/6/6/2000562.Abstract N2-背景-Coronavirus疾病爆发（2019年爆发）（Covid-19），与中国其他地区相比，在湖北省接受治疗的患者的疾病严重程度和死亡率一致且相当大的差异。我们试图比较在湖北省内外接受治疗的患者的临床特征和结果，并探索这些差异的因素。与国家卫生委员会合作的方法，我们建立了一个回顾性的队列，以研究中国的COVID-19病例。临床特征，严重事件和死亡的发生率以及重症疾病（侵入性通气或重症监护病房的入院或死亡）的时间，比较了湖北部和外部的患者之间。与武汉相关的暴露的影响（假定的关键因素驱动了湖北部的严重情况，因为武汉是居民以及湖北省的行政中心），也确定了症状发作和接受预后的持续时间。 the data cut-off (31 January 2020), 1590 cases from 575 hospitals in 31 provincial administrative regions were collected (core cohort). The overall rate of severe cases and mortality was 16.0% and 3.2%, respectively. Patients in Hubei (predominantly with Wuhan-related exposure, 597 (92.3%) out of 647) were older (mean age 49.7 versus 44.9 years), had more cases with comorbidity (32.9% versus 19.7%), higher symptomatic burden, abnormal radiologic manifestations and, especially, a longer waiting time between symptom onset and admission (5.7 versus 4.5 days) compared with patients outside Hubei. Patients in Hubei (severe event rate 23.0% versus 11.1%, death rate 7.3% versus 0.3%, HR (95% CI) for critical illness 1.59 (1.05–2.41)) have a poorer prognosis compared with patients outside Hubei after adjusting for age and comorbidity. However, among patients outside Hubei, the duration from symptom onset to hospitalisation (mean 4.4 versus 4.7 days) and prognosis (HR (95%) 0.84 (0.40–1.80)) were similar between patients with or without Wuhan-related exposure. In the overall population, the waiting time, but neither treated in Hubei nor Wuhan-related exposure, remained an independent prognostic factor (HR (95%) 1.05 (1.01–1.08)).Conclusion There were more severe cases and poorer outcomes for COVID-19 patients treated in Hubei, which might be attributed to the prolonged duration of symptom onset to hospitalisation in the epicentre. Future studies to determine the reason for delaying hospitalisation are warranted.This study highlights the necessity of urgent and vigorous support of healthcare resources and increased public awareness during the early stages of an outbreak of COVID-19 or similar diseases https://bit.ly/39OWFf0 ER -